Loading
EPHA7 (Ephrin type-A receptor 7) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer, Neuroendocrine tumours, Colorectal cancer and 2 more.
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Among GPI-anchored ephrin-A ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their interaction regulates brain development modulating cell-cell adhesion and repulsion.
Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.94, genetic association 0.28, somatic mutation 0.50, clinical 0.93). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Colorectal Adenocarcinoma, Hepatocellular Carcinoma, Lung Adenocarcinoma.
In plain words · EPHA7 (Ephrin type-A receptor 7) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer, Neuroendocrine tumours, Colorectal cancer and 2 more.
EPHA7 (Ephrin type-A receptor 7) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer, Neuroendocrine tumours, Colorectal cancer and 2 more.
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells.
No product in this corpus aims at EPHA7 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA EPHA7: RNA tissue enriched (parathyroid gland 66 nTPM); high antibody staining in 8 normal tissues; highest cancer staining pancreatic cancer (1 of 8 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Thyroid cancer, Neuroendocrine tumours, Colorectal cancer, Hepatocellular carcinoma, Lung cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (medullary thyroid gland carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q15375; IntOGen EPHA7; Human Protein Atlas EPHA7 tissue; Open Targets ENSG00000135333 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Fox G.M. et al, Oncogene, 1995, "cDNA cloning and tissue distribution of five human EPH-like receptor protein-tyrosine kinases". Source.
Sources: HGNC HGNC:3390 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q15375 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000135333 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: thyroid cancer 0.62, neuroendocrine neoplasm 0.61 (GraphQL API, CC0)); IntOGen EPHA7 (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Among GPI-anchored ephrin-A ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their interaction regulates brain development modulating cell-cell adhesion and repulsion. Has a repellent activity on axons and is for instance involved in the guidance of corticothalamic axons and in the proper topographic mapping of retinal axons to the colliculus. May also regulate brain development through a caspase(CASP3)-dependent proapoptotic activity. Forward signalling may result in activation of components of the ERK signalling pathway including MAP2K1, MAP2K2, MAPK1 and MAPK3 which are phosphorylated upon activation of EPHA7. Location: Cell membrane (UniProt). Locus 6q16.1 (HGNC).
RNA: tissue enriched (parathyroid gland 66 nTPM), detected in many normal tissues.
Medium: Adrenal gland, Appendix, Bone marrow, Breast, Bronchus, Cerebral cortex, Endometrium, Fallopian tube.
RNA cancer enhanced: Kidney Renal Clear Cell Carcinoma 8 pTPM, Kidney Renal Papillary Cell Carcinoma 10 pTPM.
Medium only: breast cancer, cervical cancer, colorectal cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"EPHA7" OR ABSTRACT:"EPHA7" OR TITLE:"EPH receptor A7" OR ABSTRACT:"EPH receptor A7" OR TITLE:"Ephrin type-A receptor 7" OR ABSTRACT:"Ephrin type-A receptor 7" OR TITLE:"Hek11" OR ABSTRACT:"Hek11") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EPHA7, not a curated reading list.
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform, Colorectal cancer.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.